



Route 206 and Province Line Road, Princeton, NJ 08543

February 20, 2026

## Bristol-Myers Squibb Company Update on Abraxane CVR Payment for Fiscal Year 2025

As previously announced, on November 20, 2019, Bristol-Myers Squibb Company (the “Company”) acquired Celgene Corporation (“Celgene”) when it consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of January 2, 2019 (“Merger Agreement”), among the Company, Burgundy Merger Sub, Inc., a wholly owned subsidiary of the Company, and Celgene. In connection with the consummation of the transactions contemplated by the Merger Agreement, the Company assumed the contingent value rights related to Celgene’s Abraxane<sup>®</sup> and Abraxis pipeline products granted by Celgene to certain holders thereof pursuant to that certain Contingent Value Rights Agreement, dated as of October 15, 2010 (as amended, supplemented or otherwise modified from time to time, the “CVR Agreement”), between Equiniti Trust Company (the “Trustee”, as successor to American Stock Transfer & Trust Company, LLC) and the Company (as successor in interest to Celgene). All capitalized terms used herein and not defined shall have the meanings assigned to such terms in the CVR Agreement.

On February 20, 2026, the Company notified the Trustee that the Net Sales for Abraxane (as defined in the CVR Agreement) for the year ended December 31, 2025 is \$367,642,907 and that there is no Net Sales Payment due in respect of the year ended December 31, 2025, in accordance with Section 3.1 of the CVR Agreement. In accordance with the terms of the CVR Agreement, December 31, 2025 shall be deemed to be the Net Sales Payment Termination Date and the Company’s obligations to pay any Net Sales Payment terminated in its entirety on the Net Sales Payment Termination Date.